scanX
Home
Zim Laboratories

Zim Laboratories

110.44
+0.51
(0.46%)
Market Cap (₹ Cr.)
₹535
52 Week High
131.40
Book Value
₹49
52 Week Low
89.50
PE Ratio
29.84
PB Ratio
2.24
PE for Sector
38.75
PB for Sector
4.65
ROE
7.22 %
ROCE
10.64 %
Dividend Yield
0.00 %
EPS
₹3.68
Industry
Pharmaceuticals
Sector
Pharmaceuticals - Indian - Bulk Drugs & Formln
Live Chart
comparison:

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Growth Rate
Revenue Growth
-7.98 %
Net Income Growth
-29.42 %
Cash Flow Change
-57.35 %
ROE
-40.77 %
ROCE
-48.67 %
EBITDA Margin (Avg.)
-13.43 %

Financial Results

Quarterly Financials
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Revenue
57
73
64
64
75
78
70
71
98
94
68
68
73
70
70
87
75
74
65
77
87
106
94
101
103
105
68
87
97
119
83
Expenses
50
61
57
55
64
62
62
61
85
81
64
63
65
62
60
80
67
65
59
67
75
90
81
87
88
89
62
76
85
102
74
EBITDA
7
12
7
9
11
16
8
10
13
13
4
5
8
8
10
6
8
9
6
10
11
15
13
14
15
16
5
10
12
17
9
Operating Profit %
10 %
13 %
11 %
13 %
15 %
12 %
11 %
14 %
13 %
13 %
4 %
7 %
10 %
9 %
14 %
7 %
10 %
12 %
8 %
11 %
12 %
13 %
12 %
12 %
13 %
14 %
7 %
11 %
12 %
13 %
10 %
Depreciation
2
2
2
2
3
3
3
3
3
3
3
3
3
4
4
4
4
4
3
4
4
4
4
4
4
5
4
4
4
4
5
Interest
3
1
2
3
2
3
3
3
3
2
3
3
3
3
3
3
2
3
3
3
2
1
1
1
2
1
2
1
2
2
3
Profit Before Tax
1
9
3
4
7
10
3
4
8
8
-3
-1
1
2
4
-0
2
3
0
3
6
10
8
8
10
10
-0
5
7
11
1
Tax
-0
3
0
1
0
-3
1
1
2
2
0
0
0
-0
1
1
1
-2
0
0
1
2
1
1
2
2
0
1
1
-1
0
Net Profit
2
11
2
3
6
7
3
3
6
5
0
-0
1
2
3
-0
2
1
0
2
4
6
6
6
7
7
-0
4
5
8
1
EPS in ₹
2.13
14.26
2.68
1.81
7.79
4.32
1.67
1.89
3.51
2.87
0.02
-0.30
0.42
0.93
1.70
-0.03
0.94
0.85
0.11
1.24
2.70
3.96
3.47
3.49
1.35
1.46
-0.03
0.86
0.99
1.62
0.16
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
265
256
259
297
325
323
320
335
335
443
Fixed Assets
87
92
89
94
101
111
103
103
107
160
Current Assets
168
154
154
172
191
176
183
201
179
218
Capital Work in Progress
6
3
4
8
13
10
10
11
26
40
Investments
0
0
0
0
5
8
8
8
8
8
Other Assets
172
161
166
195
206
194
199
213
193
234
Total Liabilities
171
157
141
161
174
171
163
165
141
211
Current Liabilities
133
122
113
141
151
143
141
145
110
162
Non Current Liabilities
38
35
28
20
22
28
22
20
30
49
Total Equity
94
99
118
136
151
152
157
170
194
232
Reserve & Surplus
86
91
110
128
135
136
141
154
145
183
Share Capital
8
8
8
8
16
16
16
16
49
49
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-7
-0
-0
1
-1
0
0
-0
1
-1
Investing Activities
-9
-12
-7
-26
-23
-19
-6
-14
-35
-72
Operating Activities
5
22
32
37
37
21
32
47
35
11
Financing Activities
-3
-10
-25
-10
-15
-2
-26
-33
1
60
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Promoter
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
33.26 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.06 %
0.00 %
0.00 %
0.01 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.11 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
66.74 %
66.74 %
66.74 %
66.74 %
66.74 %
66.74 %
66.74 %
66.74 %
66.74 %
66.68 %
66.74 %
66.74 %
66.73 %
66.63 %

Dividend History

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
1,919.95 4,62,183.91 43.83 49,887.17 12.06 9,648 42.62 69.11
Cipla
1,664.85 1,33,571.58 30.05 26,520.66 14.17 4,155 17.77 58.51
Dr Reddys Laboratories
6,749.10 1,12,773.77 20.26 28,905.40 12.36 5,578 -0.90 52.91
Zydus Life Science
1,080.35 1,07,501.01 25.79 19,831.50 13.82 3,831 30.78 42.63
Mankind Pharma
2,578.95 1,01,024.42 51.48 10,615.63 19.57 1,942 9.89 57.29
Lupin
2,194.40 99,904.51 44.14 20,141.50 19.94 1,936 77.69 52.16
Aurobindo Pharma
1,438.30 85,599.77 23.86 29,559.25 17.55 3,169 61.17 35.32
Alkem Laboratories
6,151.25 72,467.15 33.71 12,978.42 9.84 1,811 91.18 54.09
Glenmark Pharmaceuticals
1,666.95 47,227.01 - 12,653.09 6.58 -1,831 96.52 50.20
Biocon
370.65 43,587.78 27.93 15,621.20 35.25 1,298 478.78 51.92

Corporate Action

Technical Indicators

RSI(14)
Neutral
46.23
ATR(14)
Less Volatile
4.59
STOCH(9,6)
Neutral
32.73
STOCH RSI(14)
Neutral
57.04
MACD(12,26)
Bearish
-0.51
ADX(14)
Weak Trend
18.08
UO(9)
Bearish
38.41
ROC(12)
Downtrend But Slowing Down
-4.36
WillR(14)
Neutral
-63.23
Bearish
5
Neutral
4
Bullish
0
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Technical Screeners
Fundamental Screeners
Candlestick Screeners
Intraday Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2024 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.